Abstract

This is a program project proposal to establish a multidisciplinary clinical research program aimed at focusing a variety of specific laboratory and clinical disciplines on investigating the disease leukemia.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA028153-07
Application #
3093229
Study Section
(SRC)
Project Start
1980-07-01
Project End
1989-01-31
Budget Start
1987-02-01
Budget End
1988-01-31
Support Year
7
Fiscal Year
1987
Total Cost
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Skinner, W L; Murray, D; Kohli, V et al. (1990) Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia. Br J Cancer 61:51-5
Kantarjian, H M; Keating, M J; Walters, R S et al. (1989) Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63:813-7
Estey, E; Smith, T L; Keating, M J et al. (1989) Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 3:257-63
Kantarjian, H M; Walters, R S; Keating, M J et al. (1989) Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer 64:16-22
Keating, M J; Kantarjian, H; Smith, T L et al. (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7:1071-80
Kantarjian, H M; Walters, R S; Smith, T L et al. (1988) Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 72:1784-9
Keating, M J; Smith, T L; Kantarjian, H et al. (1988) Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2:403-12
Kantarjian, H M; Dixon, D; Keating, M J et al. (1988) Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441-6
Kantarjian, H M; Walters, R S; Keating, M J et al. (1988) Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62:672-6
Walters, R S; Kantarjian, H M; Keating, M J et al. (1988) Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62:677-82

Showing the most recent 10 out of 57 publications